FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Fate Therapeutics
Tizona Therapeutics, Inc
Pfizer
M.D. Anderson Cancer Center
Fate Therapeutics
Hoffmann-La Roche
Fate Therapeutics
ISU Abxis Co., Ltd.
Eli Lilly and Company
Masonic Cancer Center, University of Minnesota
Merrimack Pharmaceuticals
Medical University of Vienna